Granulocyte—macrophage colony‐stimulating factor inhibits tumour growth

A. D.K. Hill, H. P. Redmond, O. M. Austin, P. A. Grace, D. Bouchier‐Hayes

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of granulocyte—macrophage colony‐stimulating factor (GM—CSF) on murine antitumour responses was examined. Sixty mice received Lewis lung carcinoma implants and were then randomized to receive GM—CSF 1 μg/day, GM—CSF 0·5 μg/day or saline for 10 days and studied with regard to tumour volume, carcass weight and food intake. Macrophage antitumour mechanisms including oxygen free radical production and nitric oxide release were studied in peritoneal macrophages after co‐culture with GM—CSF in vitro and in vivo. GM—CSF 1 μg/day decreased tumour growth after 5 days (mean(s.e.m.) 0·62(0·4) versus 1·24(0·19) cm3, P = 0·017). GM—CSF upregulated macrophage antitumour mechanisms by enhancing the in vivo production of superoxide radicals (mean(s.e.m.) 0·69(0·06) versus 0·45(0·10) nmol, P < 0·05) and nitric oxide (mean(s.e.m.) 48(3) versus 24(4) μmol, P < 0·01). GM—CSF functions through the enhancement of macrophage tumoricidal activity, suggesting a therapeutic potential for this cytokine in the tumour‐bearing host.

Original languageEnglish
Pages (from-to)1543-1546
Number of pages4
JournalBritish Journal of Surgery
Volume80
Issue number12
DOIs
Publication statusPublished - Dec 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Granulocyte—macrophage colony‐stimulating factor inhibits tumour growth'. Together they form a unique fingerprint.

Cite this